Matos Eliana Dias, Lemos Antônio Carlos Moreira, Bittencourt Carolina, Mesquita Cristiane Leite
Octávio Mangabeira Hospital, Salvador, Bahia.
Braz J Infect Dis. 2007 Jun;11(3):331-8. doi: 10.1590/s1413-86702007000300007.
Anti-tuberculosis drug resistance, particularly multiresistance, is a crucial issue in the control of tuberculosis (TB). This study estimated the prevalence of primary and acquired anti-tuberculosis drug resistance in strains of Mycobacterium tuberculosis isolated from hospitalized patients, to identify the risk factors for resistance, and to evaluate the its impact on hospital mortality for tuberculosis. Strains of Mycobacterium tuberculosis from 217 patients hospitalized for TB were analyzed. Subjects were recruited sequentially at a TB reference hospital in Salvador, Bahia, Brazil from July 2001 to July 2003. Multiresistant (MR) strains were defined as strains resistant to rifampicin and isoniazid. Of a total of 217 strains isolated, 41 (19.0%, 95%CI: 14.1-24.5%) were resistant to at least one drug. Prevalence of primary resistance was 7.0% (10/145), while a prevalence of 43.1% (31/72) was found for acquired resistance. Primary resistance to one drug alone was found in 2.1% (3/145) and acquired monoresistance in 5.6% (4/72). Prevalence of MR strains in general was 14.3% (31/217), of which 4.2% (6/145) consisted of primary MR and 34.7% (25/72) of acquired MR. Three strains showed resistance to more than one drug, but were not classified as MR. In the multivariate analysis, abandoning treatment remained strongly associated with resistance (adjusted OR: 7.21; 95%CI: 3.27-15.90; p<0.001) following adjustment for 3 potential confounders (gender, alcohol dependence and HIV-infection). An association was found between resistance and mortality from tuberculosis, even after adjustment for HIV status, age, sex and alcohol dependence (adjusted OR: 7.13; 95%CI: 2.25-22.57; p<0.001). High prevalences of resistance, principally acquired resistance including MR, were found in patients hospitalized for TB in Bahia. This finding was strongly associated with having abandoned treatment, and confirmed the need to standardize the procedure for requesting sensitivity tests in this population at the time of hospital admission.
耐多药结核病,尤其是多重耐药性,是结核病控制中的一个关键问题。本研究估计了从住院患者中分离出的结核分枝杆菌菌株的原发性和获得性抗结核药物耐药性的流行情况,以确定耐药性的危险因素,并评估其对结核病医院死亡率的影响。对217例因结核病住院的患者的结核分枝杆菌菌株进行了分析。研究对象于2001年7月至2003年7月在巴西巴伊亚州萨尔瓦多的一家结核病参考医院依次招募。多重耐药(MR)菌株定义为对利福平及异烟肼耐药的菌株。在总共分离出的217株菌株中,41株(19.0%,95%置信区间:14.1 - 24.5%)对至少一种药物耐药。原发性耐药的患病率为7.0%(10/145),而获得性耐药的患病率为43.1%(31/72)。仅对一种药物的原发性耐药在2.1%(3/145)中发现,获得性单耐药在5.6%(4/72)中发现。总体MR菌株的患病率为14.3%(31/217),其中原发性MR占4.2%(6/145),获得性MR占34.7%(25/72)。有三株菌株对不止一种药物耐药,但未归类为MR。在多变量分析中,在对三个潜在混杂因素(性别、酒精依赖和HIV感染)进行调整后,放弃治疗仍然与耐药性密切相关(调整后的比值比:7.21;95%置信区间:3.27 - 15.90;p<0.001)。即使在对HIV状态、年龄、性别和酒精依赖进行调整后,仍发现耐药性与结核病死亡率之间存在关联(调整后的比值比:7.13;95%置信区间:2.25 - 22.57;p<0.001)。在巴伊亚州因结核病住院的患者中发现了高耐药率,主要是包括MR在内的获得性耐药。这一发现与放弃治疗密切相关,并证实了在该人群入院时规范药敏试验申请程序的必要性。